JP2010534670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534670A5 JP2010534670A5 JP2010518342A JP2010518342A JP2010534670A5 JP 2010534670 A5 JP2010534670 A5 JP 2010534670A5 JP 2010518342 A JP2010518342 A JP 2010518342A JP 2010518342 A JP2010518342 A JP 2010518342A JP 2010534670 A5 JP2010534670 A5 JP 2010534670A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocyclyl
- aryl
- alkyl
- heteroaryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 159
- 125000000623 heterocyclic group Chemical group 0.000 claims 158
- 125000003118 aryl group Chemical group 0.000 claims 152
- 125000001072 heteroaryl group Chemical group 0.000 claims 136
- 125000000753 cycloalkyl group Chemical group 0.000 claims 129
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 117
- 125000003710 aryl alkyl group Chemical group 0.000 claims 111
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 104
- 125000005843 halogen group Chemical group 0.000 claims 87
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 83
- 125000004093 cyano group Chemical group *C#N 0.000 claims 80
- 125000004104 aryloxy group Chemical group 0.000 claims 77
- 125000001188 haloalkyl group Chemical group 0.000 claims 70
- 229910052739 hydrogen Inorganic materials 0.000 claims 68
- 239000001257 hydrogen Substances 0.000 claims 68
- 125000000304 alkynyl group Chemical group 0.000 claims 65
- 125000003342 alkenyl group Chemical group 0.000 claims 61
- 150000002431 hydrogen Chemical class 0.000 claims 52
- 229910052717 sulfur Inorganic materials 0.000 claims 49
- 229910052760 oxygen Inorganic materials 0.000 claims 44
- 125000005842 heteroatom Chemical group 0.000 claims 37
- 125000004432 carbon atom Chemical group C* 0.000 claims 25
- 229910052799 carbon Inorganic materials 0.000 claims 18
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- -1 heterocyclylal Le Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 C[C@@]1*C2(CC2)C*1 Chemical compound C[C@@]1*C2(CC2)C*1 0.000 description 5
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95147807P | 2007-07-24 | 2007-07-24 | |
| US60/951,478 | 2007-07-24 | ||
| US8152908P | 2008-07-17 | 2008-07-17 | |
| US61/081,529 | 2008-07-17 | ||
| PCT/US2008/070804 WO2009015166A1 (en) | 2007-07-24 | 2008-07-23 | Piperidine derivatives as modulators of chemokine receptor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534670A JP2010534670A (ja) | 2010-11-11 |
| JP2010534670A5 true JP2010534670A5 (enExample) | 2011-03-03 |
| JP5292400B2 JP5292400B2 (ja) | 2013-09-18 |
Family
ID=39817116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518342A Expired - Fee Related JP5292400B2 (ja) | 2007-07-24 | 2008-07-23 | ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8536198B2 (enExample) |
| EP (1) | EP2173714B9 (enExample) |
| JP (1) | JP5292400B2 (enExample) |
| CN (1) | CN101808990B (enExample) |
| WO (1) | WO2009015166A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| EP2454235A1 (en) | 2009-07-16 | 2012-05-23 | Abbott Laboratories | Processes for the synthesis of (2s, 3ar, 7as)-octahydro-1h-indole carboxylic acid as an intermediate for trandolapril |
| US8877749B2 (en) | 2009-10-07 | 2014-11-04 | Bristol-Myers Squibbs Company | Spirocyclic compounds as modulators of chemokine receptor activity |
| US8410139B2 (en) * | 2009-10-07 | 2013-04-02 | Bristol-Myers Squibb Company | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
| US8642622B2 (en) * | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| GB201318222D0 (en) * | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| CN116874466A (zh) | 2018-09-21 | 2023-10-13 | 辉瑞公司 | 用作ccr6抑制剂的n-取代二氧代环丁烯基氨基-3-羟基-吡啶甲酰胺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429213B1 (en) | 1998-06-17 | 2002-08-06 | Bristol Myers Squibb Pharma Co | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US6489354B1 (en) * | 1999-03-02 | 2002-12-03 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| CA2413418A1 (en) * | 2000-06-21 | 2001-12-27 | Joseph B. Santella | Piperidine amides as modulators of chemokine receptor activity |
| MXPA02012712A (es) * | 2000-06-30 | 2003-04-25 | Bristol Myers Squibb Pharma Co | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. |
| AU2003236500B9 (en) | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| EP1763347A4 (en) | 2004-06-28 | 2009-05-20 | Incyte Corp | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS |
| AP2006003849A0 (en) * | 2004-06-28 | 2006-12-31 | Incyte Corp | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors |
| GB0525957D0 (en) * | 2005-12-21 | 2006-02-01 | Astrazeneca Ab | Methods |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US7615556B2 (en) * | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
-
2008
- 2008-07-23 JP JP2010518342A patent/JP5292400B2/ja not_active Expired - Fee Related
- 2008-07-23 CN CN200880108518XA patent/CN101808990B/zh not_active Expired - Fee Related
- 2008-07-23 WO PCT/US2008/070804 patent/WO2009015166A1/en not_active Ceased
- 2008-07-23 US US12/670,025 patent/US8536198B2/en active Active
- 2008-07-23 EP EP08796435.9A patent/EP2173714B9/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009524691A5 (enExample) | ||
| JP2010534670A5 (enExample) | ||
| JP2010534669A5 (enExample) | ||
| JP4926943B2 (ja) | Ｉｌ−１２産生を阻害する二塩 | |
| JP6008937B2 (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| JP2019031560A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2005194283A5 (enExample) | ||
| JP2016512515A5 (enExample) | ||
| JP2018520161A5 (enExample) | ||
| JP2006524669A5 (enExample) | ||
| JP2016508505A5 (enExample) | ||
| EA022964B1 (ru) | Соединения, ингибирующие ферменты гистондеацетилазы, и фармацевтическая композиция, содержащая данные соединения | |
| JP2013532652A5 (enExample) | ||
| JP2015502387A5 (enExample) | ||
| HUE026170T2 (en) | Substituted nicotinamides as modulators of KCNQ2 / 3 | |
| JP2013533883A5 (enExample) | ||
| JP2013510825A5 (enExample) | ||
| JP2019510787A5 (enExample) | ||
| JP2020502047A5 (enExample) | ||
| JP2007246474A5 (enExample) | ||
| JP2016507502A5 (enExample) | ||
| PT2578574E (pt) | Derivado de dibenzilamina opticamente activo, e processo para a sua fabricação | |
| JP7648528B2 (ja) | モノマーおよびマルチマー抗ｈｂｖ薬 | |
| JP2016512227A5 (enExample) |